Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline Activity-Clinical Practice Guideline: Treatment of Hypercalcemia of Malignancy in Adults

Clinical Practice Guideline: Treatment of Hypercalcemia of Malignancy in Adults

Pdf Summary

Hypercalcemia of malignancy (HCM) is a common complication of cancer, and a clinical guideline has been developed to provide recommendations for its treatment in adults. The guideline suggests using intravenous bisphosphonates or denosumab for adults with HCM compared to no treatment. Denosumab may be preferred over bisphosphonates and calcitonin can be added for severe cases. Denosumab is recommended for refractory/recurrent HCM on bisphosphonate treatment. For hypercalcemia due to parathyroid carcinoma, calcimimetics, bisphosphonates, or denosumab may be used. The guideline aims to guide medical management and highlight areas for further research. Clinical judgment should guide treatment choices.

Keywords

Hypercalcemia of malignancy

cancer complication

clinical guideline

treatment recommendations

intravenous bisphosphonates

denosumab

calcitonin

severe cases

refractory/recurrent HCM

parathyroid carcinoma


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274